Key result
SD-3212 terminated atrial flutter in all seven dogs and significantly increased atrial flutter cycle length from 126 to 166 ms (p < 0.005).
p-value: p=<0.005
SD-3212 effectively interrupts canine atrial flutter by suppressing atrial conduction, suggesting potential utility for clinical atrial tachyarrhythmias.
May support further preclinical testing of SD-3212; leaves open translation to human atrial tachyarrhythmias.
SD-3212 (levo-semotiadil fumarate) is a newly developed compound that exhibits potent antiarrhythmic activity because of its inhibitory action on sodium and calcium channels. In animal models, SD-3212 suppressed ventricular tachyarrhythmias, but the effects of this drug on atrial tachyarrhythmias have not been reported. We investigated the electrophysiologic effects of SD-3212 on canine atrial flutter induced after placement of the intercaval obstacle and on atrial action-potential characteristics. In all seven dogs, SD-3212 (1.9 +/- 0.3 mg/kg) terminated atrial flutter after significant increase in atrial flutter cycle length from 126 +/- 5 to 166 +/- 14 ms (increase, 31 +/- 8%; p < 0.005). SD-3212 increased right atrial effective refractory period (RAERP) significantly from 126 +/- 7 to 149 +/- 11 ms at a basic cycle length of 300 ms. The increases in RAERP after SD-3212 at basic cycle lengths of 300, 200, and 150 ms did not differ (increase, 18 +/- 4%, 17 +/- 3%, and 19 +/- 3%, respectively). Interatrial conduction time (IACT) was prolonged after SD-3212 from 63 +/- 4 to 81 +/- 6 ms (increase, 31 +/- 6%) at a basic cycle length of 150 ms. Prolongation of IACT was frequency dependent. The plasma concentration of SD-3212 after the termination of atrial flutter was 187 +/- 56 ng/ml in four dogs tested. In vitro study by using standard microelectrode techniques showed SD-3212 at concentrations of 1-3 microM significantly prolonged action-potential duration at 90% repolarization. Vmax was decreased by SD-3212 in a concentration-dependent manner (0.3-3 microM), and the inhibitory effect on Vmax was greatest at the highest stimulation frequency of 3.3 Hz. These results indicate that a new antiarrhythmic drug, SD-3212, is effective in interrupting canine atrial flutter, possibly by suppressing atrial conduction, and might be effective for the treatment of clinical atrial tachyarrhythmias.
No takes yet. Share an insight, caveat, or question.
Fujiki et al. (1997) studied Canine atrial flutter (n=7). SD-3212 (levo-semotiadil fumarate) was evaluated on Atrial flutter cycle length (p=<0.005). SD-3212 terminated atrial flutter in all seven dogs and significantly increased atrial flutter cycle length from 126 to 166 ms (p < 0.005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: